DEF 14A: NovoCure Seeks Shareholder Approval for 2024 Omnibus Incentive Plan

Sentiment:

Proxy Statement 22 April 2024 4:00 PM

NovoCure is asking shareholders to approve the 2024 Omnibus Incentive Plan to replace the 2015 plan, aiming to continue attracting and retaining key talent through equity-based awards.

Summary

NovoCure is seeking shareholder approval for the 2024 Omnibus Incentive Plan to replace the 2015 plan, which will terminate upon approval of the new plan.
The company is requesting approval for 9,000,000 shares for issuance under the 2024 Plan, less any shares subject to awards granted under the 2015 Plan after April 2, 2024, and prior to the effective date of the 2024 Plan.
If approved, the 2024 Plan will become effective on June 5, 2024, and no new awards will be granted under the 2015 Plan.
The 2024 Plan aims to secure and retain employees, executive officers, and directors, and to provide long-term incentives that align their interests with those of shareholders.
The company believes the requested share pool is adequate to cover equity awards for the next one to two years.
The 2024 Plan includes provisions designed to protect shareholders' interests, such as governance by the Compensation Committee, no automatic vesting upon change in control, and a prohibition on repricing share options without shareholder approval.
The plan allows for a broad array of equity incentives, including share options, share appreciation rights, restricted share awards, and performance-based share awards.
The company's burn rate for 2023 was 2.65%, for 2022 was 2.20% and for 2021 was 0.97%.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining the details of the proposed 2024 Omnibus Incentive Plan. While it emphasizes the benefits of the plan for attracting and retaining talent, it also acknowledges potential risks if the plan is not approved. The sentiment is moderately positive, reflecting the company's efforts to align executive compensation with shareholder interests and maintain a competitive edge in the industry.

Positives

The 2024 Plan does not have an automatic replenishment feature (also known as an evergreen provision).
The 2024 Plan includes provisions designed to protect shareholders' interests, such as governance by the Compensation Committee, no automatic vesting upon change in control, and a prohibition on repricing share options without shareholder approval.
The plan allows for a broad array of equity incentives, including share options, share appreciation rights, restricted share awards, and performance-based share awards.
The company monitors its annual burn rate, dilution, and equity expense to ensure it maximizes shareholder value.

Negatives

If the 2024 Plan is not approved, the company may need to significantly increase the cash component of employee compensation to continue to attract and retain key talent.

Risks

If the 2024 Plan is not approved, the company will lose access to an important compensation tool that is key to its ability to attract, motivate, reward, and retain key employees and Non-Employee Directors.
If the 2024 Plan is not approved, the company could be at a significant disadvantage relative to its competitors for recruiting, retaining and motivating those individuals who are critical to its success.

Future Outlook

The company anticipates the requested share pool is adequate to cover equity awards for the next one to two years.

Management Comments

Our Board believes that the 2024 Plan is necessary to ensure that the number of shares available for issuance is sufficient to allow us to continue to attract and retain the services of talented individuals essential to our long-term growth and financial success.
Our Board strongly believes that the issuance of equity awards is a key element underlying our ability to attract, retain and motivate our employees, including our executive officers, and is a substantial contributing factor to our success and the growth of our business.

Industry Context

The company faces strong competition for talent from its peers, and equity awards allow it to effectively compete for talent.

Comparison to Industry Standards

The company uses industry benchmarks to competitively grant the appropriate number of equity awards necessary to attract, reward, and retain employees and Non-Employee Directors.
The company monitors its annual burn rate, dilution and equity expense to ensure it maximizes shareholder value.
The company benchmarks its executive and director compensation levels and practices against a peer group of medical device, diagnostics and biopharmaceuticals companies including 10x Genomics, Inc., Guardant Health, Abiomed, Inc., Horizon Therapeutics Public Ltd Co, Align Technology, Incyte Corporation, Alnylam Pharmaceuticals, Inc., Inspire Medical Systems, Inc., BeiGene, Insulet Corporation, CRISPR Therapeutics AG, Seagen, Inc., DexCom, Inc., Teladoc Health, Inc., Exact Sciences Corporation and Zai Lab Limited.

Stakeholder Impact

Approval of the 2024 Omnibus Incentive Plan is expected to benefit shareholders by aligning executive compensation with long-term company performance.
Employees are expected to benefit from the plan through increased opportunities for equity ownership and long-term incentives.

Next Steps

Shareholders will vote on the approval of the 2024 Omnibus Incentive Plan at the Annual General Meeting on June 5, 2024.

Key Dates

Date	Description
2003	EY Global has audited our financial statements since 2003.
2004	William Doyle has been involved with our Company as either an investor or an employee since 2004.
2011	Kinyip Gabriel Leung was the Vice Chairman of our Board and an employee of Novocure from 2011 to 2016.
2012	Asaf Danziger has served as our Chief Executive Officer since 2002.
2015	We are seeking shareholder approval of the 2024 Plan as a successor to our 2015 Omnibus Incentive Plan.
October 10, 2016	One of our subsidiaries entered into an employment agreement with Asaf Danziger pursuant to which Mr. Danziger serves as our Chief Executive Officer.
May 2016	William Vernon has served as our Lead Independent Director since May 2016.
July 25, 2018	One of our subsidiaries entered into an employment agreement with Pritesh Shah pursuant to which Mr. Shah served as our Chief Commercial Officer.
September 1, 2020	One of our subsidiaries entered into an employment agreement with Wilhelmus Groenhuysen pursuant to which Mr. Groenhuysen serves as our Chief Operating Officer.
September 1, 2020	One of our subsidiaries entered into an employment agreement with Ashley Cordova pursuant to which Ms. Cordova serves as our Chief Financial Officer.
September 1, 2020	One of our subsidiaries entered into an employment agreement with Francis Leonard pursuant to which Mr. Leonard served as our Chief Development Officer.
April 1, 2022	One of our subsidiaries entered into an employment agreement with Barak Ben-Arye pursuant to which Mr. Ben-Arye serves as our General Counsel.
September 19, 2022	Mr. Leonard became our President, CNS Cancers US.
January 17, 2023	Mr. Shah became our Chief Growth Officer.
February 2023	Dr. Ocean was elected to our Board in February 2023.
March 2023	Ms. Stafford was elected to our Board in March 2023.
January 1, 2024	Mr. Shah resigned as Chief Growth Officer and became Senior Advisor to the Chief Executive Officer.
January 4, 2024	Mr. Leonard became our Executive Vice President, President Novocure Oncology.
April 2, 2024	Record Date
April 4, 2024	The 2024 Plan was adopted by our Board on April 4, 2024, subject to shareholder approval.
April 22, 2024	On or about April 22, 2024, we are making this Proxy Statement available on the Internet and are mailing the Notice of Internet Availability to all shareholders entitled to vote at the Annual Meeting.
June 5, 2024	Annual General Meeting of Shareholders to be held on June 5, 2024.

Keywords

Omnibus Incentive Plan, equity awards, executive compensation, shareholder approval, incentive plan, NovoCure

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.